Abstract：Objective To study the prognostic value of hematogones (HGs) for childhood B-lineage acute lymphoblastic leukemia (B-ALL) during consolidation chemotherapy. Methods A retrospective analysis was conducted for 196 children with newly-diagnosed B-ALL. They were divided into high-risk group (n=55), intermediate-risk group (n=69), and low-risk group (n=72) by risk stratification, and into complete remission group (n=165) and relapse group (n=31) by clinical outcome. The European BIOMED-1 standard flow cytometry for minimal residual disease (MRD) was used to determine the number of HGs during consolidation chemotherapy. The Kaplan-Meier survival curve was used to assess event-free survival (EFS). Results The high-risk group had a significantly lower number of HGs than the intermediate-risk and low-risk groups (PP1.0% (PConclusions HGs can be used to assess the treatment outcome and prognosis in children with B-ALL, and proliferation of HGs reflects the good effect of chemotherapy in such children.
WANG Yue-Fang,JIANG Yong-Mei,GAO Ju et al. Prognostic value of bone marrow hematogones in childhood B-lineage acute lymphoblastic leukemia[J]. CJCP, 2016, 18(4): 292-296.
Hurford MT, Altman AJ, DiGiuseppe JA, et al. Unique pattern of nuclear TdT immunofluorescence distinguishes normal precursor B cells (Hematogones) from lymphoblastsof precursor B-lymphoblastic leukemia[J]. Am J Clin Pathol, 2008, 129(5): 700-705.
[2]
Sevilla DW, Colovai AI, Emmons FN, et al. Hematogones: a review and update[J]. Leuk Lymphoma, 2010, 51(1): 10-19.
[3]
M c K e n n a RW, Wa s h i n g t o n LT, A q u i n o D B, e t a l . Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry[J]. Blood, 2001, 98(8): 2498-2507.
[4]
Chantepie SP, Cornet E, Salaün V, et al. Hematogones: an overview[J]. Leuk Res, 2013, 37(11): 1404-1411.
[5]
Chantepie SP, Salaün V, Parienti JJ, et al. Hematogones: a new prognostic factor for acute myeloblastic leukemia[J]. Blood, 2011, 117(4): 1315-1318.
[6]
Honebrink T, Dayton V, Burke MJ, et al. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia[J]. Biol Blood Marrow Transplant, 2012, 18(6): 930-936.
[7]
Shima T, Miyamoto T, Kikushige Y, et al. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation[J]. Blood, 2013, 121(5): 840-848.
[8]
Lucio P, Gaipa G, van Lochem EG, et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings[J]. Leukemia, 2001, 15(8): 1185-1192.
Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study[J]. Blood, 2008, 111(12): 5477-5485.
[11]
Tsao L, Colovai AI, Jiang JG, et al. Characterizing CD43 expression in haematogones using multicolor flow cytometric analysis[J]. Br J Haematol, 2005, 128(6): 820-823.
[12]
LeBien TW. Fates of human B-cell precursors[J]. Blood, 2000, 96(1): 9-23.
[13]
LeBien TW, Tedder TF. B lymphocytes: how they develop and function[J]. Blood, 2008, 112(5): 1570-1580.
[14]
van der Sluijs-Gelling AJ, van der Velden VH, Roeffen ET, et al. Immunophenotypic modulation in childhood precursor B-ALL can be mimicked in vitro and is related to the induction of cell death[J]. Leukemia, 2005, 19(10): 1845-1847.
[15]
Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a druginduced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group[J]. Cytometry B Clin Cytom, 2010, 78(3): 147-153.
[16]
Chantepie SP, Dugue AE, Chevallier P, et al. Prognostic impact of bone marrow B lymphocyte precursors (hematogones) detection in 95 acute lymphoblastic leukemia cases[C]. ASH Annu Meeting Abstr, 2012, 120: 4791.
[17]
Zheng J, Du W, Yao J, et al. Analysis of hematogones in bone marrow from acute myeloid leukaemia cases post therapy[J]. Eur J Clin Invest, 2013, 43(1): 1140-1146.
